1. Introduction {#sec1}
===============

Parasitic nematodes infect around one billion people, with the soil transmitted nematodes Ascaris, hookworm and whipworm (*Trichuris trichiura*) each afflicting hundreds of millions of people ([@bib16]). These diseases cause high morbidity and are closely linked to poverty in the developing world. The global impact of parasitic nematodes is worsened by their effect on livestock, equids and companion animals. Parasitic nematodes of livestock are thought to cost approximately \$10 billion annually with anthelmintic products comprising a major segment of the veterinary pharmaceuticals market ([@bib49]).

There are concerns that mass drug administration (MDA) programs aimed at controlling or eradicating human parasitic nematodes will be made unsustainable by anthelmintic resistance, jeopardising attempts to eradicate these important tropical diseases ([@bib46]). In the case of *Trichuris,* modelling indicates that existing benzimidazole drugs are insufficiently effective for single dose MDA programs designed to break transmission; therefore eradication cannot be achieved ([@bib21], [@bib25], [@bib63]). The current arsenal of veterinary anthelmintics is threatened by the emergence and spread of resistance in parasitic nematodes of domesticated animals, a recent example of which is the report of resistance to monepantel in sheep nematode species only four years after introduction of the compound ([@bib51], [@bib53]). Multi-class resistance is also common in parasitic nematodes of ruminants ([@bib50], [@bib59]) and equids ([@bib35]). Thus, there is an urgent requirement for the identification of novel classes of anthelmintics.

Phenotypic screening is enjoying a resurgence in recent years and is playing an increasingly important role in the modern drug discovery paradigm ([@bib2]). Furthermore, employment of this approach using live nematodes *ex vivo* has been historically successful for target identification and lead optimisation. For example, a series of acetonitrile derivatives were identified using a *Haemonchus contortus in vitro* larval development assay, and this led to the discovery of monepantel ([@bib20]).

1.1. Automated systems for phenotypic screening of parasitic nematodes and models of parasites {#sec1.1}
----------------------------------------------------------------------------------------------

Given the need for new anthelmintics, there has been growing interest both in phenotypic screens for identification of new classes of active small molecules and in systems for quantifying relevant readouts of nematode viability such as growth and motility ([@bib4], [@bib5]). Manual scoring of motility, growth or viability has been effective and used to screen libraries of up to 67,000 compounds ([@bib7], [@bib62], [@bib61]). Automated systems offer the potential of higher throughput and greater reliability. Such approaches include indirect assessment of viability by using the xCELLigence System; assessment of metabolic activity via colorimetric assays such as resazurin, MTT, and acid phosphatase activity; assessment of motor activity via isothermal microcalorimetry and quantification of movement-related light scattering ([@bib37], [@bib55], [@bib56], [@bib66], [@bib67]).

Imaging-based systems for quantification of motility or growth have also been developed. The "WormAssay" system quantifies the motility of macroscopic parasites such as *Brugia malayi* adult worms ([@bib30]). This system has been further developed into "The Worminator", which quantifies smaller, microscopic nematode stages and has been validated by quantifying the activity of several anthelmintics ([@bib58]). This system has a reported scan time of 30 s per well, hence a throughput of around one and a quarter 6-well plates per hour. A system based on single-well imaging and thresholding of motile pixels with a throughput of around five 96-well plates per hour has been reported ([@bib44]). Its utility has been demonstrated by the successful screening of a 522-compound kinase inhibitor library and the 400-compound Medicine for Malaria Venture Pathogen box on *Haemonchus contortus* larvae ([@bib43], [@bib45]). A notable recently-described screen of the effects of 26,000 compounds on *Caenorhabditis elegans* growth/survival used WormScan, a system that uses a conventional flat-bed scanner to capture two frames of images of whole plates and then uses an algorithm based on the difference image to assign a value to each well that reflects motility/growth ([@bib33], [@bib34]). This led to the identification of several compounds with previously unreported anthelmintic activity, including compounds targeting PINK-1 and MEV-1. The authors reported a throughput of approximately 25--40 96-well plates per hour.

1.2. Developing a new robust motility/growth quantification system focussed on rapid, high-throughput chemical screening {#sec1.2}
------------------------------------------------------------------------------------------------------------------------

It is clear that recent developments in phenotypic screening of parasitic and model nematodes have led to an acceleration of the discovery of potential novel anthelmintic compounds. Given the large sizes of drug-like compound libraries and the need to efficiently identify the hit compounds therein that have the potential to be developed into potent and selective anthelmintic lead molecules, it is desirable that nematode phenotypic screening be further accelerated. Here, we present the development of the INVAPP/Paragon system, which quantifies nematode motility/growth with a throughput of approximately 100 96-well plates per hour, with a robust and unbiased approach. We validate the system by quantifying the activity of a panel of known anthelmintics on a variety of nematode species, and then by screening, in a blinded fashion, the Medicines for Malaria Venture Pathogen Box for compounds that block or reduce nematode growth.

2. Materials and methods {#sec2}
========================

2.1. Ethics statement {#sec2.1}
---------------------

All mouse experiments were approved by the University of Manchester Animal Welfare and Ethical Review Board and performed under the regulation of the United Kingdom Home Office Scientific Procedures Act (1986) and the Home Office project licence 70/8127.

All ovine experiments were approved by the Moredun Research Institute Experiments and Ethics Committee and performed under the regulation of the United Kingdom Home Office Scientific Procedures Act (1986) and the Home Office project licence 60/04421.

2.2. INVAPP/Paragon system {#sec2.2}
--------------------------

The INVAPP/Paragon system consists of a fast high-resolution camera (Andor Neo, resolution 2560x2160, maximum frame rate 100 frames per second) with a line-scan lens (Pentax YF3528). Microtiter plates are placed in a holder built into the cabinet and imaged from below. Illumination is provided by an LED panel with acrylic diffuser. Movies were captured using μManager ([@bib13]). The desirable movie frame length and duration of filming depends on the particular organism under study and is specified below. Movies were analysed using MATLAB scripts. Briefly, movies were analysed by calculating the variance through time for each pixel. The distribution of these pixel variances was then considered, and pixels whose variance was above the threshold (typically those greater than one standard deviation away from the mean variance) were considered 'motile'. Motile pixels were assigned by well, by dividing the matrix evenly across the width and height of the image, with plateColumns and plateRows parameters used to specify the number of wells in the plate image. The 'motile' pixels were then counted, generating a movement score for each well. The source code for this software has been released under the open source MIT license and is available at <https://github.com/fpartridge/invapp-paragon>. A further MATLAB script has been provided for batch processing of movies.

2.3. *Caenorhabditis elegans* motility and growth assays {#sec2.3}
--------------------------------------------------------

*C. elegans* strains were maintained at 20 °C on nematode growth medium agar seeded with the *E. coli* strain OP50. To obtain worms for screening, a mixed-stage liquid culture was prepared by washing well-fed worms from one small NGM plate into a medium of 50 ml S-complete buffer with a pellet of approximately 2--3 g *E. coli* HB101. Cultures were agitated at 200 rpm, 20 °C, until there were many adults present, then synchronised at the L1 stage by bleaching. Fifty millilitre cultures were pelleted and bleaching mix (1.5 ml 4M NaOH, 2.4 ml NaOCl, 2.1 ml water) added. Mixing for 4 min led to the release of embryos, which were washed three times with 50 ml S-basal medium. The cultures were incubated in 50 ml S-basal at 20 °C and agitated at 200 rpm overnight to allow eggs to hatch and arrest as a synchronous L1 population.

For the growth assay, *C. elegans* were cultured in a 96-well plate format. Synchronised L1 were diluted to approximately 20 worms per 50 μl in S complete medium with around 1% w/v HB101 *E. coli*. Assay plates were prepared with 49 μl of S-basal and 1  μl of DMSO or compound in DMSO solution per well. Next, 50 μl of the L1 suspension were added to each well. Final DMSO concentration was 1% v/v. Plates were incubated at 20 °C before imaging using the INVAPP/Paragon system 5 days later. Prior to imaging, worm motion was stimulated mechanically by inserting and removing a 96-well PCR plate into/from the wells of the assay plate. Whole-plate 200 frame movies were recorded at 30 frames per second (7 s total).

For the adult motility assay, synchronised L1 were refed as a bulk 50 ml culture and cultured at 20 °C until they developed into young adults. Worms were washed in S-basal and dispensed, approximately 20 worms per well, into 96-well plates with compound dissolved in DMSO, or DMSO alone and then incubated for 3 h. Final DMSO concentration was 1% v/v. Whole-plate 200 frame movies were recorded at 30 frames per second (7 s total).

For the anthelmintic panel screen using *C. elegans* in the acute treatment adult motility assay and the growth assay, we screened n = 5 wells for each concentration, with each replicate concentration on different plates. Where the compound was active in the assay, we fitted a dose-response curve using 3-parameter log-logistic model and the R package *drc* ([@bib47]).

2.4. *Trichuris muris* motility assay {#sec2.4}
-------------------------------------

For the adult *T. muris* motility assay, male and female severe combined immune deficiency mice (bred in the Biological Services Facility at the University of Manchester) were infected with 200 embryonated *T. muris* eggs in water by oral gavage. After 35 days, mice were killed and their caecae and colons removed, opened longitudinally, and washed with pre-warmed Roswell Park Memorial Institute (RPMI) 1640 media supplemented with penicillin (500 U/ml) and streptomycin (500 μg/ml). Adult *T. muris* worms were then removed using fine forceps and maintained in RPMI-1640/penicillin/streptomycin media at approximately 37 °C and studied on the same day. Individual live worms were placed into 96 well plates containing 75 μl of RPMI-1640/penicillin/streptomycin medium plus 1% v/v final concentration of DMSO or compound dissolved in DMSO. Plates were incubated at 37 °C, 5% v/v CO~2~, and motility was analysed after 24 h. Whole plate 200 frame movies were recorded at 10 frames per second (20 s total).

2.5. Ovine parasitic nematode isolation {#sec2.5}
---------------------------------------

Six month-old, male Texel cross lambs that were raised under helminth-free conditions were infected *per os* either with 15,000 *T. circumcincta* (isolate MTci2) larvae (L~3~) or 5000 *H. contortus* (isolate MHco3) L~3~. Once a patent infection was detected by the observation of nematodes eggs in faeces (around 21 days post-infection), the lambs were fitted with a collection harness and bag to enable faecal collection. Pelleted faeces were collected from each bag 24 h later and placed in a covered seed tray, which was incubated at room temperature (\>15 °C) for 10 days before larval recovery using the modified Baermann technique ([@bib29]). The next day L~3~ were recovered in ∼250 ml H~2~O, number estimation performed then the larvae were stored in 100 ml tap water in 75 cm^2^ surface area vented cap, suspension culture flasks (Sarstedt Ltd UK) at ∼ 5 °C for MTci2 and 8 °C for MHco3, respectively.

2.6. *T. circumcincta* assay {#sec2.6}
----------------------------

Ensheathed L3 *T. circumcincta* were used in this assay, which are the infective form of the parasite that is ingested by the grazing host. Approximately 30 worms were added to wells containing compound + DMSO or DMSO alone (final concentration 1% v/v). Worms were incubated for 2 h in the dark at 25 °C. Movement was stimulated by illuminating the plate with bright white light for 3 min (Zeiss HAL100), before acquiring movies on the INVAPP/Paragon system (200 frames, 10 frames per second).

2.7. *H. contortus* assay {#sec2.7}
-------------------------

*H. contortus* exsheathed L3 (xL3) were prepared by treatment with sodium hypochlorite. A 1 ml solution containing around 1000 *H. contortus* L3 was placed in a 35 mm petri dish. 20 μl sodium hypochlorite solution (Fisher, S/5040/PC17) was added and incubated at room temperature for 4 min. Exsheathment was monitored using a dissecting microscope. The worms were filtered using a 10 μm cell strainer (pluriSelect), rinsed with 10 × 1 ml S-basal solution, and eluted with 1 ml S-basal solution. Around 30 xL3 worms (in S-basal solution) were added to wells containing compound + DMSO or DMSO alone (final DMSO concentration 1% v/v). Worms were incubated for 2 h in the dark at 25 °C. Movement was stimulated by illuminating the plate with bright white light for 3 min (Zeiss HAL100), before acquiring movies on the INVAPP/Paragon system (200 frames, 30 frames per second). The INVAPP/Paragon *movementIndexThreshold* parameter was set to 2 for analysis of *H. contortus xL3*, due to a lower prior expectation of worm movement in the movie for this nematode.

2.8. Pathogen Box screening {#sec2.8}
---------------------------

The Pathogen Box library was obtained from the Medicines for Malaria Venture as 10 mM solutions in DMSO, and then diluted in DMSO to 1 mM. It was then screened in the *C. elegans* growth assay as described (final concentration 10 μM, n = 5, 1% v/v final DMSO). Solid material for confirmatory screening of actives was obtained from Sigma-Aldrich (tolfenpyrad) and Santa Cruz Biotechnology (auranofin). Solid samples of MMV007920, MMV020152, MMV652003 and MMV688372 were obtained from the Medicines for Malaria Venture.

3. Results {#sec3}
==========

3.1. INVAPP/Paragon: a high-throughput assay for quantifying nematode motility and growth {#sec3.1}
-----------------------------------------------------------------------------------------

We wanted to develop an assay for screening small molecules for their effect on the motility and growth of diverse parasites. A high-throughput and automated system was particularly desirable, given the large size of available small molecule libraries. To this end, we designed the INVAPP/Paragon system. A schematic of the INVAPP hardware is shown in [Fig. 1](#fig1){ref-type="fig"}A. This allows recording of movies of entire microplates at high frame rate, reducing the per plate acquisition time to 10--30 s. Tens of thousands of compounds or conditions can therefore be readily screened per day.Fig. 1**The INVAPP /Paragon movement index algorithm is a fully-automated high-throughput system able to determine motility and growth rate.** (A) Schematic of the INVAPP setup (B) Principle of the algorithm: thresholding of moving pixels by statistical analysis of variance of each pixel through time. Histogram shows the distribution of pixel variance over time. Data was from obtained from a movie of all wells in a single 96-well plate containing wild-type *C. elegans*. The distribution is obtained by counting the number of pixels that fall into each bin of log pixel variance over time. Blue vertical line indicates mean pixel variance. The green vertical line indicates mean plus standard deviation of pixel variance; the blue shaded portion of the histogram indicates pixels that exceed this threshold so are deemed to be 'motile'. (C) Image of 96-well plate containing *C. elegans* adults processed by the INVAPP/Paragon movement index system. Dark pixels are those categorized as moving by the algorithm. (D) Increasing the number of *C. elegans* worms per well leads to increase in reported movement index. Boxplot bars indicate 95% confidence interval. Dataset contains 16 wells per group from a single 96-well plate. (E) Movement index algorithm is able to quantify *C. elegans* growth in 96-well plates. Movement index increases with growth. Synchronised L1 population refed on day 0. Decrease in movement index in 25 °C group on Day 4 reflects completion of the *C. elegans* lifecycle and exhaustion of the bacterial food source. Boxplot notches indicate 95% confidence interval, n = 192 wells of worms for each of the 20 °C and 25 °C groups. (F) Absence of edge effects in this assay -- analysis of a 1920-well *C. elegans* growth dataset shows no difference of the normalised movement score for 96-well plate outer edge wells (the wells found in columns 1 and 12 or rows A and H) compared to the score for inner wells (the other wells in the plate). Dataset is from a total of 20 96-well plate movies obtained from *C. elegans* grown at 20 °C, 25 °C and 26 °C to show that this assay is robust over a range of experimentally useful temperatures. Movement index for each well is normalised by dividing by the mean movement index for all wells of that plate. The blue bar indicates median. (G) No edge effects or other inhomogeneity across the plate -- heat map shows average normalised movement index for each well location. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 1

We took a statistical approach to quantifying motility. The variance through time for each pixel in the plate was calculated and the distribution of the variances examined. Pixels whose variance is greater than a threshold of the mean plus typically one standard deviation are determined to be "motile" ([Fig. 1](#fig1){ref-type="fig"}B). For organisms that are particularly small or have limited motility, such as *H. contortus* L3s, this threshold was increased to the mean plus two standard deviations, reflecting a lower prior expectation of worm movement in the movie. A similar approach was recently reported for the determination of *H. contortus* motility ([@bib43]). An example of this thresholding model is shown in [Fig. 1](#fig1){ref-type="fig"}C, which shows analysis of a 96-well plate containing uniformly-treated, adult, wild-type *C. elegans*. Dark pixels are those that have been determined to be motile. Once the motility threshold has been applied to the data, 'motile' pixels are assigned by well to their plate location and counted. All analysis is fully automated via a set of MATLAB scripts, available at <https://github.com/fpartridge/invapp-paragon> ([@bib40]).

This approach was able to quantify motility. To illustrate this, we analysed plates containing a variable number of synchronised adult *C. elegans* worms. As expected, quantified movement increased with the number of worms per well, reflecting a larger number of 'motile' pixels in the recording ([Fig. 1](#fig1){ref-type="fig"}D).

The system was also able to quantify nematode growth. To test this, we synchronised *C. elegans* at the L1 stage, before refeeding them in plates at two temperatures commonly used in *C. elegans* culture (20 °C and 25 °C). Plates were then analysed using INVAPP/Paragon every 24 h. The results are shown in [Fig. 1](#fig1){ref-type="fig"}E. The quantified movement index increases as worms develop from L1 to adult stage. The drop in motility in the 25 °C group on day 5 reflects growth of L1 progeny leading to exhaustion of the bacterial food source and starvation.

When establishing a high-throughput assay it is important to consider the issue of edge effects ([@bib28]). Systematic biases across the plate are particularly common around edges. Typical causes are evaporation, which is often worse at the edges, or temperature inhomogeneity. In our assay, given that it involves imaging of whole plates, we also wanted to exclude the possibility of systemic bias caused by optical distortion. To address these concerns, we analysed a 1920-well *C. elegans* growth dataset. This was chosen because the long four-day incubation time gave the maximum possibility of confounding evaporation differences. We classified wells on the outer rows and columns of the plate as being outer wells, and compared their quantified motility to the inner wells ([Fig. 1](#fig1){ref-type="fig"}F). There was no significant difference between these groups (Mann-Whitney-Wilcoxon test, P = 0.77), and therefore no evidence of problematic edge effects in this assay. To further exclude the possibility of assay inhomogeneity across the plate, we calculated a heat map showing average normalised motility for each well ([Fig. 1](#fig1){ref-type="fig"}G). Again, this showed no evidence of systemic bias by plate position.

3.2. Validation of the INVAPP/Paragon assay using existing commercial anthelmintic standards {#sec3.2}
--------------------------------------------------------------------------------------------

Having set up this high-throughput motility and growth assay, we wanted to validate its utility by examining the effects of a panel of known anthelmintics. We selected nine anthelmintics with a variety of reported mechanisms of action. Piperazine is a GABA agonist that acts at the neuromuscular junction ([@bib31]). Diethylcarbamazine has been proposed to have a similar mechanism, although other mechanisms including targeting host arachidonic acid metabolism are also thought to be important ([@bib27]). Levamisole, oxantel and pyrantel are nicotinic acetylcholine receptor agonists that induce spastic paralysis ([@bib32]). Mebendazole is an inhibitor of beta-tubulin polymerisation ([@bib12]). Ivermectin is a positive allosteric modulator of glutamate-gated chloride channels although other targets have also been suggested ([@bib9]). Trichlorfon is a member of the organophosphate group of acetylcholine esterase inhibitors. Praziquantel is thought to act by disrupting calcium ion homeostasis but its target is unclear ([@bib8]).

We first measured concentration-response curves for this panel of anthelmintics in an acute treatment (3 h) adult *C. elegans* assay. The results are shown in [Fig. 2](#fig2){ref-type="fig"}. As expected, the major ion channel-targeting drugs ivermectin, levamisole, oxantel and pyrantel were active in this assay, reflecting their direct effects on worm motility.Fig. 2**Determination of the effect of acute treatment (3 h) with important anthelmintics on *C. elegans* adult motility using the INVAPP/Paragon movement index algorithm.** Blue line fitted using the 3-parameter log-logistic model. EC~50~ values are shown in parentheses, with standard error for this estimate calculated using *drc* ([@bib47]). Each dot indicates movement score for one well. n = 5 wells for each concentration, with each replicate concentration on different plates. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 2

We then measured concentration-response curves for this panel of anthelmintics in a chronic treatment *C. elegans* growth assay (5 days, 20 °C, from L1 stage). The results are shown in [Fig. 3](#fig3){ref-type="fig"}. Activity was again found with ivermectin, levamisole, oxantel and pyrantel and, additionally, with mebendazole, piperazine and trichlorfon. This reflects that some anthelmintic modes of action may not be measured in purely acute motility assays (at least for shorter-lived nematodes such as *C. elegans*), supporting the use of assays that involve growth or development. Indeed, an action of macrocyclic lactones distinct from that on motility has been proposed ([@bib69]). Diethylcarbamazine and praziquantel were not active in these assays as expected. This reflects previously reported low *in vitro* activity of diethylcarbamazine and its proposed mechanism of acting on host arachidonic acid metabolism ([@bib27]). Praziquantel, used primarily to treat flukes and tapeworms, is known to have limited efficacy against nematodes ([@bib15]). Successfully demonstrating the ability of the INVAPP/Paragon system to determine the effects of known anthelmintics increased our confidence in this approach.Fig. 3**Determination of the effect of important anthelmintics on *C. elegans* growth using the INVAPP/Paragon movement index algorithm.** Chronic treatment for 5 days from L1 stage. Blue line fitted using the 3-parameter log-logistic model. EC~50~ values are shown in parentheses, with standard error for this estimate calculated using *drc* ([@bib47]). Each dot indicates movement score for one well. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 3

3.3. Adaptation of the INVAPP/Paragon assay to parasitic nematodes {#sec3.3}
------------------------------------------------------------------

*C. elegans* is a useful model because of the ease of laboratory culture and access to powerful genetic tools. However, it is also valuable to screen parasitic nematodes directly. *T. circumcincta* is a globally important parasitic nematode that infects small ruminants. We tested the ability of the INVAPP/Paragon system to quantify the activity of the anthelmintic ivermectin on ensheathed *T. circumcincta* L3. Worms were incubated at 25 °C with the compounds for 2 h in the dark, after which movement was induced by bright light and movies recorded on the INVAPP system. [Fig. 4](#fig4){ref-type="fig"}A shows an example of the INVAPP/Paragon motility thresholding of single wells treated with DMSO or DMSO plus 100 μM ivermectin, showing much reduced, but not abolished movement, of these larvae in the assay. We obtained a concentration-response curve for ivermectin ([Fig. 4](#fig4){ref-type="fig"}B), demonstrating the ability of the system to quantify motility of this parasite.Fig. 4**Utilising the INVAPP/Paragon system with ensheathed L3 *T. circumcincta*.** (A) INVAPP/Paragon motility thresholding of single wells treated with DMSO or a DMSO solution of ivermectin (assay concentration 100 μM). Black pixels show those scored as being 'motile' by the software. (B) Concentration-response curve for treatment with the anthelmintic ivermectin, n = 4. Each replicate was carried out in different experimental sessions, using one batch of L3 *T. circumcincta*. Curve fitted using the four-parameter log-logistic function. Error range on the EC~50~ estimate indicates standard error (delta method).Fig. 4

*H. contortus,* the barber\'s pole worm, is another economically important gastrointestinal parasite of small ruminants. We tested the ability of the INVAPP/Paragon system to quantify the activity of ivermectin on exsheathed L3 (xL3) *H. contortus.* Worms were incubated at 25 °C with the compounds for 2 h in the dark, after which movement was induced by bright light and movies recorded on the INVAPP system. An example of the INVAPP/Paragon motility thresholding of single wells treated with DMSO or a DMSO solution of ivermectin (assay concentration 100 μM) is shown in [Fig. 5](#fig5){ref-type="fig"}A. Movement of ivermectin-treated xL3s in the assay was considerably reduced. A concentration-response curve for ivermectin is shown in [Fig. 5](#fig5){ref-type="fig"}B, illustrating the ability of the system to quantify motility of this parasite. A caveat to these results, regarding their potential translation to *in vivo* potency, is that under physiological conditions *H. contortus* becomes exsheathed in the stomach at 38--41 °C. Therefore activity in this assay at 25 °C may not fully reflect the *in vivo* action of ivermectin.Fig. 5**Utilising the INVAPP/Paragon system with exsheathed L3 *H. contortus*.** (A) INVAPP/Paragon motility thresholding of single wells treated with DMSO or a DMSO solution of ivermectin (assay concentration 100 μM). Black pixels show those scored as being 'motile' by the software. (B) Concentration-response curve for treatment with the anthelmintic ivermectin, n = 4. Each replicate drug treatment was carried out in different experimental sessions, each time freshly exsheathing the worms by bleach treatment, using one batch of ensheathed L3 *H. contortus*. Curve fitted using the four-parameter log-logistic function. Error range on the EC~50~ estimate indicates standard error (delta method).Fig. 5

*Trichuris muris,* which infects mice, is a widely used laboratory model for investigating trichuriasis and has been used as a system for *ex vivo* and *in vivo* testing of anthelmintic candidates for activity against whipworm ([@bib17], [@bib62], [@bib68]). We tested the ability of the INVAPP/Paragon system to quantify the activity of the anthelmintic levamisole on adult *T. muris*. Worms were incubated at 37 °C with the compounds for 24 h in the dark, after which movement was recorded on the INVAPP system. [Fig. 6](#fig6){ref-type="fig"}A shows control and levamisole treated wells. For illustration, selected frames of the movie are shown (3 second intervals). The readout of 'motile' pixels as determined by the INVAPP/Paragon algorithm is shown in [Fig. 6](#fig6){ref-type="fig"}B, showing the quantification of the loss of motility of the levamisole-treated worm. A concentration-response curve for levamisole was measured ([Fig. 6](#fig6){ref-type="fig"}C), which illustrates the ability of the system to quantify motility of this parasite and thus measure anthelmintic activity.Fig. 6**Utilising the INVAPP/Paragon system with adult *T. muris*.** (A) Example of section of movie, showing control and levamisole-treated wells. Selected movie frames are shown at 3-s intervals (B) Pixels for these wells that are considered to be motile as determined by the algorithm are shown in red. (C) Concentration-response curves for treatment with the anthelmintic levamisole, n = 4 wells per concentration, each replicate well on different plates using independent batches of *T. muris* from different mice, over 2 experimental sessions. Curve fitted using the three-parameter log-logistic function. Error range on the EC~50~ estimate indicates standard error (delta method). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 6

3.4. Screening the Pathogen Box for compounds that affect *C. elegans* growth {#sec3.4}
-----------------------------------------------------------------------------

We then applied the INVAPP/Paragon assay system to the identification of novel anthelmintic small molecules. We used the Pathogen Box, a collection of 400 diverse drug-like molecules that are known to be active against various neglected disease pathogens (particularly, tuberculosis (or *Mycobacterium* spp.), malaria and kinetoplastid protozoa). This library is distributed as an open-science project by the Medicines for Malaria Venture. A screen of this library for compounds affecting motility of exsheathed L3 of *H. contortus* has been published recently ([@bib45]), which identified the insecticide, tolfenpyrad, as active against the larvae. To complement this approach, and with the aim of identifying compounds blocking growth of nematodes as opposed to solely immobilising them, we screened the library in a blinded fashion (5 separate library plate sets in total, using worms from 2 separately prepared batches of *C. elegans* L1 larvae, experiment conducted on 2 different occasions, final compound concentration 10 μM) using the INVAPP/Paragon *C. elegans* growth assay. For each compound, motility change and significance (Mann-Whitney-Wilcoxon test) were calculated relative to DMSO-only control wells. A volcano plot showing the results of this screen is shown in [Fig. 7](#fig7){ref-type="fig"}A. Compounds that reproducibly reduced growth are found towards the top left of this plot. To confirm identity of the hit molecules, we retested the top 20 putative hit compounds in a secondary screen with the same library material (n = 5, concentration 10 μM) in the same INVAPP/Paragon *C. elegans* growth assay ([Fig. 7](#fig7){ref-type="fig"}B). A total of 18 out of 20 compounds were active (P \< 0.05, Dunnett\'s multiple comparison test).Fig. 7**Screening the Pathogen Box in the *C. elegans* growth screen.** (A) Volcano plot showing the results of the primary screen (n = 5 replicates per compound, concentration = 10 μM, each replicate was on different plates, over two experimental sessions). Each point represents one compound. Effective size is shown on the x axis, as log~2~-fold change (ratio of the median movement for the repeats of the compound to the median movement of DMSO-only wells). Statistical significance is shown on the y axis as the -log~10~ P value in the Mann-Whitney-Wilcoxon test. A location at the top left of this plot indicates anthelmintic activity. (B) Secondary rescreen of hit compounds, using library material, in order of their activity in the primary screen. Statistical significance compared to DMSO-only control calculated by Dunnett\'s multiple comparison test (n = 5, \* indicates P \< 0.05, \*\* indicates P \< 0.005, \*\*\*\* indicates P \< 0.0005). (C,D,E) Concentration-response curves showing the activity of known anthelmintics -- (C) tolfenpyrad, (D) auranofin, (E) isradipine -- that were found in the Pathogen box screen retested using solid material (supplied by the Medicines for Malaria Venture) in the *C. elegans* growth assay. A concentration-response curve for mebendazole in the assay was presented in [Fig. 3](#fig3){ref-type="fig"}. Error bars indicate standard deviation, n = 4 wells per concentration per compound. Curve fitting was undertaken using three parameter log logistic model (Graphpad Prism).Fig. 7

The combined assay results from the primary and secondary screen are found in [Supplementary File 1](#appsec1){ref-type="sec"} and have been recorded in the PubChem database with Assay ID 1259336.

3.5. Identification of known anthelmintic compounds by screening the Pathogen Box in the *C. elegans* growth assay {#sec3.5}
------------------------------------------------------------------------------------------------------------------

We first considered known anthelmintic compounds that we found to be active in this screen ([Table 1](#tbl1){ref-type="table"}). Mebendazole, an anthelmintic from the benzimidazole group, acts by inhibiting microtubule synthesis ([@bib24]). Tolfenpyrad is a broad-spectrum acaricide and insecticide that acts as an inhibitor of complex I of the electron transport chain ([@bib70]). It has been recently reported to reduce motility of *H. contortus* exsheathed L3 and to block L3 to L4 development of this parasite *in vitro* ([@bib45]). We confirmed activity of this compound using solid material. As shown in [Fig. 7](#fig7){ref-type="fig"}C, the EC~50~ was 200 ± 40 nM. Independently identifying these known anthelmintic compounds using a blinded screening approach further validates the INVAPP/Paragon system as a robust high throughput screening approach.Table 1**Named compounds that were active in the *C. elegans* growth screen.** Log~2~-fold change in growth estimate compared to DMSO-only controls. Hit ID is as in [Fig. 7](#fig7){ref-type="fig"}B. EC~50~ confidence interval is the standard error. The EC~50~ estimate for mebendazole is from [Fig. 3](#fig3){ref-type="fig"}. Primary and secondary screens used solutions supplied as part of the Pathogen Box Library. EC~50~ estimates were determined using solid material.Table 1CompoundMMV IDPubChem CIDHit IDLog~2~ fold change in growthEC~50~ (μM) ± standard error(1° screen)(2° screen)(solid material)TolfenpyradMMV68893410,110,5361−10.9−10.60.2 ± 0.04AuranofinMMV68897824,199,3132−10.9−7.21.1 ± 0.3MebendazoleMMV00315240305−6.0−5.71.1 ± 0.2IsradipineMMV001493158,61716−2.2−1.41.6 ± 0.7Tavaborolen/a11,499,245n/an/a8.6 ± 1.9

Auranofin is a gold(I) compound originally developed for the treatment of rheumatoid arthritis. It has received attention for repurposing as an anti-cancer agent, with a number of clinical trials under way. It has been shown that auranofin has *in vitro* and *in vivo* activity in several models of parasitic diseases, including schistosomiasis ([@bib22]), amoebiasis ([@bib11]), leishmaniasis ([@bib54]) and onchocerciasis ([@bib6]). A phase IIa trial of auranofin for gastrointestinal protozoal infection is ongoing. We confirmed activity of this compound in the *C. elegans* growth assay using solid material. As shown in [Fig. 7](#fig7){ref-type="fig"}D, the EC~50~ of this compound was 1.1 ± 0.3 μM.

Isradipine is an antihypertensive drug that belongs to the dihydropyridine family of L-type calcium channel blockers. A structurally related dihydropyridine, nemadipine-A, has been shown to cause growth and egg laying defects in *C. elegans* by antagonising the L-type calcium channel α~1~-subunit EGL-19 ([@bib23]). We confirmed activity of this compound in the *C. elegans* growth assay using solid material. As shown in [Fig. 7](#fig7){ref-type="fig"}E, the EC~50~ of this compound was 1.6 ± 0.7 μM.

3.6. Assessment of screen performance {#sec3.6}
-------------------------------------

The pathogen box screen was screened blindly without the addition of positive control compounds. However we wanted to assess the performance of the screen. We therefore treated wells containing mebendazole as positive controls for comparison against negative control DMSO-only wells. We then calculated the strictly standardized mean difference (SSMD) parameter, which is a principled statistical assessment of high-throughput screen performance ([@bib3], [@bib72], [@bib71]). For the positive control mebendazole we calculated that SSMD β = −2.54. This indicates that screen performance was adequate to good (for a strong control −3 \< β \< −2 is considered good).

3.7. Novel anthelmintics that block *C. elegans* growth {#sec3.7}
-------------------------------------------------------

Fourteen compounds without previously-described anthelmintic activity were identified in the Pathogen Box screen ([Table 2](#tbl2){ref-type="table"}). The structures of the most active compounds are shown in [Fig. 8](#fig8){ref-type="fig"}. We examined four of these compounds more closely. First, we determined activity, using solid material, in the *C. elegans* growth assay ([Fig. 9](#fig9){ref-type="fig"}). The EC~50~ values for the confirmatory assay are shown in [Table 2](#tbl2){ref-type="table"}. These results have been recorded in the PubChem database with Assay ID 1259335.Fig. 8**Structures of the most active compounds, previously undescribed as anthelmintics, which were found to have activity in the *C. elegans* growth screen.** Compound numbers from Medicines for Malaria Venture Pathogen Box.Fig. 8Fig. 9**Concentration-response relationships for selected hit compounds in the *C. elegans* growth screen,** using solid material supplied by Medicines for Malaria Venture. (A) MMV007920 (B) MMV020152 (C) MMV652003 (D) MMV688372. N = 4 wells per concentration per compound. Curve fitting was undertaken using three parameter log logistic model (Graphpad Prism).Fig. 9Table 2**Compounds with previously unreported anthelmintic activity that were active in the *C. elegans* growth screen.** MMV ID is the compound identifier for the Medicines for Malaria Venture. PubChem CID is the compound identifier for the PubChem database. Hit ID is as in [Fig. 7](#fig7){ref-type="fig"}B. Log~2~ fold change in the growth estimate in the INVAPP/Paragon assay compared to DMSO-only controls. Primary and secondary screens used solutions supplied as part of the Pathogen Box Library. EC~50~ estimates were determined using solid material, supplied by the Medicines for Malaria Venture.Table 2MMV IDPubChem CIDHit IDLog~2~ fold change in growthEC~50~ (μM)(1° screen)(2° screen)(solid material)MMV65200346,196,1103−8.9−7.64.3 ± 2.5MMV007920721,1334−7.0−5.46.2 ± 2.4MMV68837272,710,5986−5.8−4.03.3 ± 1.7MMV67599444,222,8027−5.7−2.0n.d.MMV02655044,530,5218−5.5−5.9n.d.MMV0203917,918,6479−5.0−2.7n.d.MMV67639554,678,16610−4.8−4.8n.d.MMV0201528,880,74012−3.1−6.92.5 ± 1.0MMV67640630,238,52614−2.7−8.0n.d.MMV68841758,346,93115−2.6−1.1n.d.MMV68893618,589,79717−2.2−3.7n.d.MMV102880616,387,38618−2.1−0.8n.d.MMV6888885,179,23619−2.0−2.1n.d.MMV68718041,058,17320−1.8−3.6n.d.

MMV007920 is a benzoxazole-containing compound previously identified in a screen for agents that inhibit *Plasmodium falciparum* proliferation. The target of this compound is not known but it has been suggested that some benzoxazole compounds act on beta-tubulin ([@bib52]). MMV020152 is an isoxazole-containing compound previously identified in a screen for compounds that inhibit *P. falciparum* growth. A number of other compounds also containing isoxazole motifs have been shown to have insecticidal activity ([@bib10]). MMV688372 is an imidazopyridine-containing compound that has been previously shown to have *in vivo* anti-trypanosomal activity ([@bib60]).

MMV652003 is a benzoxaborole-containing compound that has also been given the identifier AN3520 in the literature. This compound has potent activity against *Trypanosoma* sp., both *in vitro*, and in murine models of human African trypanosomiasis ([@bib36]). In this context this compound has been iteratively improved leading to the identification of the close relative SCYX-7158 ([@bib18]), which is currently in clinical trials. The anti-trypanosomal target of this benzoxaborole class is not known ([@bib19]). A simpler benzoxaborole compound, tavaborole ([Fig. 10](#fig10){ref-type="fig"}B), has been approved as an anti-fungal ([@bib14]). This acts by inhibiting cytoplasmic leucyl-tRNA synthetase by forming an adduct with tRNA^Leu^ in the enzyme editing site ([@bib48]). Benzoxaborole anthelmintic agents are being developed by Anacor/Eli Lilly ([@bib1], [@bib73]). Benzoxaborole compounds also show promise for other infectious diseases, including malaria, cryptosporidiosis, toxoplasmosis and tuberculosis, in each case acting via inhibition of leucyl-tRNA synthetase ([@bib38], [@bib39], [@bib57]).Fig. 10**Benzoxaborole compounds as anthelmintics.** Structures of (A) the screen hit MMV652003 and (B) the related benzoxaborole tavaborole, which is approved as an anti-fungal. (C) Concentration-response curve for tavaborole in the *C. elegans* growth assay. N = 5 wells per concentration. Blue line fitted using three parameter log logistic model with drc ([@bib47]). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 10

Given the effect of MMV652003 and the similarity of this compound to the already approved drug tavaborole, we determined whether tavaborole was effective in the *C. elegans* growth assay. Tavaborole showed concentration-dependent growth inhibition ([Fig. 10](#fig10){ref-type="fig"}C) with an EC~50~ of 8.6 ± 1.9 μM ([Table 1](#tbl1){ref-type="table"}). This is similar to that of the benzoxaborole screen hit, MMV652003, which has an EC~50~ of 4.3 ± 2.5 μM ([Table 1](#tbl1){ref-type="table"}). These results support the development of a benzoxaborole anti-nematode agent.

4. Discussion {#sec4}
=============

There is an urgent need for new anthelmintics. Despite encouraging progress with MDA programs, current strategies and therapies will not achieve eradication of, for example, *T. trichiura* ([@bib21], [@bib63]). Furthermore, MDA, particularly with drugs that do not fully clear infection, may lead to drug resistance ([@bib65]). The experience from veterinary parasitology is that resistance to new anthelmintics can develop relatively rapidly after registration, causing major economic impacts and risks to global food security ([@bib51], [@bib53]).

In this manuscript, we present the INVAPP/Paragon system which, based on imaging of whole microplates and thresholding pixel variance to determine motion, is able to quantify growth and/or motility of parasitic nematodes and the free-living nematode, *C. elegans.* A strength of this system is its high-throughput capability, typically imaging a whole plate for 5--20 s is sufficient to reliably quantify motion in all 96 wells. We demonstrated this effect by determining efficacy of a panel of anthelmintics in both acute motility and growth assays in *C. elegans* and of known anthelmintics in *H. contortus, T. circumcincta,* and *T. muris* assays. We further demonstrated utility of the system in a screen of small molecules for compounds that block or limit *C. elegans* growth. Current anthelmintic screens generally focus on motility reduction, as growth of parasitic nematodes can be difficult to model *in vitro,* with larvae failing to moult through their larval stages outside of the host. However anthelmintic activity *in vivo* can be much broader than inhibition of motility and thus screening compounds for their ability to inhibit *C. elegans* growth, rather than motility, represents a useful strategy to identify compounds which can subsequently be tested for growth inhibition activity *in vivo.* We used the Pathogen Box, a library of a collection of 400 diverse drug-like molecules known to be active against various neglected diseases, distributed as an open-science project by the Medicines for Malaria Venture.

Identifying the compounds with known anthelmintic or anti-parasitic activity mebendazole and tolfenpyrad ([@bib45]) using independent blinded screening approach serves as an important validation and supports the robustness of the screening platform. Repurposing of existing drugs for new indications is an established approach in drug discovery ([@bib74]) and is particularly valuable for neglected tropical diseases as it may reduce research and development costs and speed progress to clinical trials ([@bib42]). Auranofin has recently been shown to have activity against filarial nematode infection ([@bib6]). Our identification of auranofin as a compound that blocks *C. elegans* growth lends support to test repurposing of this compound for nematode infections. Isradipine, a safe and well-tolerated L-type calcium channel blocker, was also active in the screen. Assaying the activity of isradipine in *in vivo* models of parasitic infection is a priority and could lead to repurposing trials.

We also identified 14 compounds with previously undescribed anthelmintic activity in the *C. elegans* growth assay, belonging to a variety of chemical classes. These include benzoxazole and isoxazole compounds previously shown to have activity against *P. falciparum* ([@bib10], [@bib52]), and an imidazopyridine-containing compound previously shown to have *in vivo* anti-trypanosomal activity ([@bib60]). Another notable active compound was the benzoxaborole, MMV652003. Since the identification and successful progression into the clinic of the anti-fungal tavaborole, a number of benzoxaborole compounds have been reported to show potential for trypanosomiasis, malaria, cryptosporidiosis, toxoplasmosis and tuberculosis ([@bib26]). These results support the idea that some drug chemotypes can have activity against a diversity of infectious agents. Given the costs of drug development and the limited resources available for the discovery of new drugs targeting neglected tropical diseases, it seems possible that an open source medicinal chemistry program could catalyse discovery for many different indications ([@bib64]). Whilst preparing this manuscript we have applied the INVAPP/Paragon system to library-scale screening measuring motility of *ex vivo T. muris* adults, which led to identification of a new class of anthelmintics, the dihydrobenzoxazepinones ([@bib41]). Taken together these results demonstrate the potential for anthelmintic discovery using this system, with new compounds with anthelmintic activity identified by screens using both the free-living nematode *C. elegans* as a parasite model, and the mouse whipworm *T. muris*.

The anthelmintic compounds we have identified in this study were active in a growth assay using *C. elegans,* which is typically considered a free-living nematode, although it undoubtedly has utility in anthelmintic drug discovery ([@bib7]). A critical step to support the development of these compounds will be to determine their activity on important human and animal parasitic nematodes. These compounds were inactive in a recently reported screen that determined their effects on motility of *H. contortus* xL3 ([@bib45]). It is therefore possible that their activity requires active growth of the target nematode, perhaps reflecting a target distinct from the neuromuscular system. A recent set of criteria for hit-to-lead progression in neglected infective diseases provides a useful guide to the steps that need to be taken to progress these early-stage hit compounds ([@bib75]). It will be particularly important to demonstrate activity against a range of nematode parasites and differential sensitivity between parasite and host to support the development of a new anthelmintic.

We focused our application of the INVAPP/Paragon system to investigating parasitic diseases. However, given its ability to determine growth and motility of *C. elegans* quickly and robustly, it could also be applied to the study of other human diseases modelled in *C. elegans.*

In conclusion, we have developed a high-throughput system for measuring the growth and/or motility of parasitic and free-living nematodes. Quantification of the activity of known anthelmintics and identification of novel chemotypes with anthelmintic activity was demonstrated, validating our approach. The system is well suited to library-scale screening of chemicals with many human and animal health applications.

Appendix A. Supplementary data {#appsec1}
==============================

The following is the supplementary data related to this article:Supplementary File 1Results of primary and secondary screens of the Pathogen Box library using the *C. elegans* growth assay.Supplementary File 1

The Pathogen Box was designed and supplied by the Medicines for Malaria Venture ([www.mmv.org](http://www.mmv.org){#intref0020}). Some *C. elegans* strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440). F.A.P. is supported by Medical Research Council ([www.mrc.ac.uk](http://www.mrc.ac.uk){#intref0025}) grant MR/N024842/1 to D.A.L. and D.B.S. and prior to that was supported by CeBioscience Ltd and a University College London Fellowship. A.E.B. is supported by a studentship from the Rosetrees Trust. R.F. is supported by Medical Research Council ([www.mrc.ac.uk](http://www.mrc.ac.uk){#intref0030}) grant MR/N022661/1 to K.J.E. D.A.L. is supported by the NIHR UCLH Biomedical Research Centre. J.B.M. and A.A.D. are funded by the Scottish Government through the Rural and Environmental Science and Analytical Services (RESAS) Division.

Supplementary data related to this article can be found at [https://doi.org/10.1016/j.ijpddr.2017.11.004](10.1016/j.ijpddr.2017.11.004){#intref0035}.
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